{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:43:37Z","timestamp":1762548217044,"version":"build-2065373602"},"reference-count":108,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18","760278\/March 26","PNRR 2024\\u20132026"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18","760278\/March 26","PNRR 2024\\u20132026"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018987","name":"Romanian Government Ministry of Research Innovation and Digitization","doi-asserted-by":"publisher","award":["PN-IV-P8-8.3-ROMD-2023-0036"],"award-info":[{"award-number":["PN-IV-P8-8.3-ROMD-2023-0036"]}],"id":[{"id":"10.13039\/100018987","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.beha.2025.101638","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:02:43Z","timestamp":1748347363000},"page":"101638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adoptive cellular therapies in multiple myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"David","family":"Kegyes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Borlea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Damian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian Bogdan","family":"Tigu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madalina","family":"Nistor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Cenariu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raluca","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Gulei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Dascalescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ion","family":"Antohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.beha.2025.101638_bib1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2025.101638_bib2","unstructured":"SEER Cancer Stat Facts: Myeloma. National Cancer Institute. Bethesda, MD [Internet]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"10.1016\/j.beha.2025.101638_bib3","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"10","author":"Mafra","year":"2024","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.beha.2025.101638_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-018-0068-5","article-title":"A systematic classification of death causes in multiple myeloma","volume":"8","author":"Mai","year":"2018","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.beha.2025.101638_bib5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/cancers17050793","article-title":"Evolution of survival in patients with multiple myeloma over two decades: a real-world experience from a medium-level hospital","volume":"17","author":"Ortega-Vida","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.beha.2025.101638_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","article-title":"Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient?","volume":"15","author":"Kegyes","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib7","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1182\/blood-2024-199913","article-title":"BCMA CAR-T therapy as first-line consolidation treatment in transplant-ineligible patients with newly-diagnosed multiple myeloma: an open label, single-arm, phase 2 study (CAREMM-001)","volume":"144","author":"Yan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101638_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T\u2010cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"American J Hematol"},{"issue":"4","key":"10.1016\/j.beha.2025.101638_bib9","article-title":"CAR T-cell therapy: adverse events and management","volume":"10","author":"Adkins","year":"2019","journal-title":"JADPRO"},{"issue":"8","key":"10.1016\/j.beha.2025.101638_bib10","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-Cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"40","key":"10.1016\/j.beha.2025.101638_bib11","doi-asserted-by":"crossref","first-page":"25764","DOI":"10.18632\/oncotarget.25359","article-title":"Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma","volume":"9","author":"Bu","year":"2018","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.beha.2025.101638_bib12","first-page":"2267","article-title":"T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Orthod"},{"issue":"18","key":"10.1016\/j.beha.2025.101638_bib13","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2025.101638_bib14","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.beha.2025.101638_bib15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.beha.2025.101638_bib16","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1080\/10428194.2021.1913143","article-title":"Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma","volume":"62","author":"Rodriguez-Otero","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.beha.2025.101638_bib17","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/bjh.19302","article-title":"Efficacy and safety of idecabtagene vicleucel in patients with relapsed\u2013refractory multiple myeloma not meeting the KarMMa \u20101 trial eligibility criteria: a real\u2010world multicentre study","volume":"204","author":"Dima","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2025.101638_bib18","first-page":"2087","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.beha.2025.101638_bib19","article-title":"Standard-of-Care idecabtagene vicleucel for relapsed\/refractory multiple myeloma: a cibmtr analysis","author":"Sidana","year":"2025","journal-title":"Blood J"},{"author":"Hashmi","key":"10.1016\/j.beha.2025.101638_bib20"},{"issue":"17","key":"10.1016\/j.beha.2025.101638_bib21","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/bloodadvances.2024013540","article-title":"Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience","volume":"8","author":"Kalariya","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101638_bib22","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-202467","article-title":"Efficacy of idecabtagene vicleucel (ide-cel) in patients with relapsed\/refractory multiple myeloma and prior central nervous system manifestation: a retrospective real-world analysis","volume":"144","author":"Maulhardt","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2025.101638_bib23","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Sidana","year":"2023","journal-title":"Haematol"},{"issue":"5","key":"10.1016\/j.beha.2025.101638_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","article-title":"Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel","volume":"4","author":"Paiva","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.beha.2025.101638_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-023-00820-y","article-title":"Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma","volume":"13","author":"Bansal","year":"2023","journal-title":"Blood Cancer J"},{"issue":"24","key":"10.1016\/j.beha.2025.101638_bib26","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.beha.2025.101638_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.beha.2025.101638_bib28","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024014476","article-title":"Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel","author":"Saha","year":"2025","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.beha.2025.101638_bib29","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/bloodadvances.2023009766","article-title":"Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma","volume":"7","author":"Lee","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.beha.2025.101638_bib30","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.2023021429","article-title":"Chemotherapy-induced reversal of ciltacabtagene autoleucel\u2013associated movement and neurocognitive toxicity","volume":"142","author":"Graham","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101638_bib31","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024028172","article-title":"Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment","author":"Blumenberg","year":"2025","journal-title":"Blood J"},{"issue":"4","key":"10.1016\/j.beha.2025.101638_bib32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib33","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2022-162469","article-title":"KarMMa-2 cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation","volume":"140","author":"Usmani","year":"2022","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.beha.2025.101638_bib34","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000970388.90596.a3","article-title":"P871: idecabtagene vicleucel (IDE-CEL) in patients with an inadequate response to frontline autologous stem cell transplantation (ASCT): results from KARMMA-2 cohort 2C","volume":"7","author":"Alsina","year":"2023","journal-title":"HemaSphere"},{"issue":"11","key":"10.1016\/j.beha.2025.101638_bib35","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.beha.2025.101638_bib36","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class\u2013exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2025.101638_bib37","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","volume":"11","author":"Delforge","year":"2024","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib38","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1182\/blood-2021-147412","article-title":"KarMMa-7, a phase 1\/2, dose-finding and dose-expansion study of combination therapies with idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy for relapsed\/refractory multiple myeloma (RRMM)","volume":"138","author":"Raje","year":"2021","journal-title":"Blood"},{"issue":"10297","key":"10.1016\/j.beha.2025.101638_bib39","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101638_bib40","first-page":"8009","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Orthod"},{"issue":"12","key":"10.1016\/j.beha.2025.101638_bib41","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000813","article-title":"Ciltacabtagene autoleucel for patients with triple-class exposed multiple myeloma: adjusted comparison of CARTITUDE-1 patient outcomes versus real-world clinical practice","volume":"6","author":"Delforge","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.beha.2025.101638_bib42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2025.101638_bib43","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3324\/haematol.2022.280482","volume":"108","author":"Mateos","year":"2022","journal-title":"Haematol"},{"issue":"9","key":"10.1016\/j.beha.2025.101638_bib44","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2024-0080","article-title":"Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting","volume":"13","author":"Alsdorf","year":"2024","journal-title":"J Comp Eff Res"},{"issue":"4","key":"10.1016\/j.beha.2025.101638_bib45","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2025.101638_bib46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib47","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2023-178882","article-title":"The phase 2 CARTITUDE-2 trial: updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B)","volume":"142","author":"Hillengass","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2025.101638_bib48","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.jtct.2023.12.054","article-title":"The phase 2 cartitude-2 trial: updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1\u20133 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B)","volume":"30","author":"Hillengass","year":"2024","journal-title":"Transplan Cellular Therapy"},{"issue":"9","key":"10.1016\/j.beha.2025.101638_bib49","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1080\/03007995.2024.2391112","article-title":"Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2\u20134 prior lines of therapy: a matching-adjusted indirect comparison","volume":"40","author":"Bar","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.beha.2025.101638_bib50","article-title":"Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma","volume":"18","author":"Hansen","year":"2025","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.beha.2025.101638_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70070","article-title":"Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study","volume":"9","author":"Merz","year":"2025","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib52","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1182\/blood-2024-211128","article-title":"Anti-BCMA CAR T-cell expansion and its association with response and toxicity in multiple myeloma","volume":"144","author":"Hosoya","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101638_bib53","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41467-023-44648-3","article-title":"Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.beha.2025.101638_bib54","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","article-title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\u20132, open-label study","volume":"9","author":"Martin","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.beha.2025.101638_bib55","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(24)00320-X","article-title":"Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial","volume":"12","author":"Mina","year":"2025","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib56","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1182\/blood-2024-212230","article-title":"Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2025.101638_bib57","doi-asserted-by":"crossref","first-page":"609.e1","DOI":"10.1016\/j.jtct.2023.06.010","article-title":"Idecabtagene vicleucel is well tolerated and effective in relapsed\/refractory myeloma patients with prior allogeneic stem cell transplantation","volume":"29","author":"John","year":"2023","journal-title":"Transplan Cellular Therapy"},{"issue":"12","key":"10.1016\/j.beha.2025.101638_bib58","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.clml.2023.08.012","article-title":"Ciltacabtagene autoleucel in patients with prior allogeneic stem cell transplant in the CARTITUDE-1 study","volume":"23","author":"Htut","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib59","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2024-210451","article-title":"Efficacy of anti-BCMA CAR-T cell therapies in multiple myeloma patients with prior exposure to bispecific antibodies- results from a retrospective multi-center registry analysis","volume":"144","author":"Waldschmidt","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101638_bib60","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.beha.2025.101638_bib61","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.beha.2025.101638_bib62","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.beha.2025.101638_bib63","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol Ther"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib64","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2023-182430","article-title":"Early safety results of P-BCMA-ALLO1, a fully allogeneic chimeric antigen receptor T-cell (CAR-T), in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"142","author":"Dholaria","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib65","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1182\/blood-2022-158231","article-title":"Universal updated phase 1 data highlights role of allogeneic anti-BCMA ALLO-715 therapy for relapsed\/refractory multiple myeloma","volume":"140","author":"Mailankody","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2025.101638_bib66","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol"},{"issue":"S3","key":"10.1016\/j.beha.2025.101638_bib67","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000970460.94543.ab","article-title":"P889: point-of-care anti-bcma CAR t-cell therapy induces encouraging response rates in high-risk relapse\/refractory multiple myeloma","volume":"7","author":"Magen","year":"2023","journal-title":"HemaSphere"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101638_bib68","first-page":"8004","article-title":"Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r\/r multiple myeloma (RRMM)","volume":"41","author":"Sperling","year":"2023","journal-title":"J Clin Orthod"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib69","doi-asserted-by":"crossref","first-page":"10307","DOI":"10.1182\/blood-2022-166011","article-title":"Phase I study of a BCMA-directed CAR-T cell therapy for relapsed\/refractory multiple myeloma manufactured in <3 Days using the high-performance platform","volume":"140","author":"Liu","year":"2022","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2025.101638_bib70","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2019-129562","article-title":"Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME)","volume":"134","author":"Costello","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib71","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood-2024-198499","article-title":"Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: preliminary results from the IMMagine-1 trial","volume":"144","author":"Freeman","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib72","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/blood-2023-185271","article-title":"High efficacy and safety of nanobody based anti-BCMA CAR-T cell therapy in treating patients with relapsed or refractory multiple myeloma","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2025.101638_bib73","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib74","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1182\/blood-2023-174364","article-title":"CD27-Armored BCMA-CAR T cell (CBG-002) therapy for relapsed and refractory multiple myeloma: a phase I clinical trial","volume":"142","author":"Xu","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib75","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2024-198225","article-title":"Efficacy of HBI0101, an anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed\/refractory multiple myeloma","volume":"144","author":"Lebel","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2025.101638_bib76","first-page":"3285","article-title":"A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"11","author":"Cornell","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib77","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.1182\/blood-2024-197883","article-title":"Promising safety and efficacy of trovocabtagene autoleucel (C-CAR088) followed ASCT in ultra high-risk multiple myeloma (UHR-MM) patients","volume":"144","author":"Xu","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib78","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2023-186619","article-title":"Phase I clinical study of humanized BCMA-single-domain antibodies-targeting CAR T (BCMA-CART) in patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Zheng","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib79","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1182\/blood-2023-184373","article-title":"Three-year follow-up on efficacy and safety results from phase 1 lummicar study 1 of zevorcabtagene autoleucel in Chinese patients with relapsed or refractory multiple myeloma","volume":"142","author":"Fu","year":"2023","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2025.101638_bib80","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1182\/blood-2019-126104","article-title":"Phase 1 trial of the safety and efficacy of fully human anti-bcma CAR T cells in relapsed\/refractory multiple myeloma","volume":"134","author":"Jie","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib81","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-184373","article-title":"Three-year follow-up on efficacy and safety results from phase 1 lummicar study 1 of zevorcabtagene autoleucel in Chinese patients with relapsed or refractory multiple myeloma","volume":"142","author":"Fu","year":"2023","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.beha.2025.101638_bib82","first-page":"8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101638_bib83","first-page":"8025","article-title":"CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed\/refractory multiple myeloma: updated results of phase 1b\/2 study (FUMANBA-1)","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Orthod"},{"issue":"17","key":"10.1016\/j.beha.2025.101638_bib84","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1158\/1078-0432.CCR-24-0414","article-title":"A 5-year follow-up clinical study of the B-cell maturation antigen chimeric antigen receptor T-cell therapy HDS269B in patients with relapsed or refractory multiple myeloma","volume":"30","author":"Chen","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.beha.2025.101638_bib85","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv"},{"issue":"485","key":"10.1016\/j.beha.2025.101638_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.beha.2025.101638_bib87","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein\u2010coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"13","key":"10.1016\/j.beha.2025.101638_bib88","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib89","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood-2024-201356","volume":"144","author":"Bal","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib90","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2023-179147","article-title":"Safety and efficacy of GPRC5D CAR T cell therapy in relapsed\/refractory multiple myeloma patients","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib91","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1182\/blood-2024-204790","article-title":"GPRC5D-Targeted CAR T-cell therapy CT071 for the treatment of refractory\/relapsed multiple myeloma","volume":"144","author":"Du","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-Targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib93","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood-2024-201356","volume":"144","author":"Bal","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101638_bib94","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41375-019-0525-6","article-title":"Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7","volume":"34","author":"Kikuchi","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.beha.2025.101638_bib95","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody\u2013drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Therapeut"},{"issue":"2","key":"10.1016\/j.beha.2025.101638_bib96","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1309\/617DWB5GNFWXHW4L","article-title":"CD138 (Syndecan-1), a plasma cell marker: immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms","volume":"121","author":"O'Connell","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.beha.2025.101638_bib97","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cellular Immunotherapy"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib98","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2023-182578","article-title":"Discovery and development of CD70 as a cellular therapy target in high risk multiple myeloma","volume":"142","author":"Kasap","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101638_bib99","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment","volume":"10","author":"Van Der Schans","year":"2020","journal-title":"Front Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib100","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1182\/blood-2024-210226","article-title":"A single-center, single-arm, phase I clinical trial of anti-BCMA\/gprc5d bispecific CAR T-cells in patients with refractory and relapsed multiple myeloma with extramedullary disease","volume":"144","author":"Qiu","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101638_bib101","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib102","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2024-204774","article-title":"Autologous B cell maturation antigen (BCMA) and CD19 dual targeting fastcar-T cells (GC012F\/AZD0120) as first-line therapy for elderly patients with newly diagnosed multiple myeloma patients","volume":"144","author":"Du","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib103","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood-2024-201160","article-title":"A prospective investigator-initiated phase 1\/2 study of BCMA\/CD19 dual-targeting CAR T therapy in patients with relapsed\/refractory multiple myeloma including those with extramedullary disease","volume":"144","author":"Jiang","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib104","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1182\/blood-2023-185085","article-title":"Development of a phase 1 study evaluating the activity of modular CAR T for multiple myeloma (MCARTY) targeting BCMA and CD19 for improved persistence","volume":"142","author":"Lee","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib105","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1182\/blood-2024-207687","article-title":"5-Year follow-up of combined infusion of anti-CD19 and anti-BCMA CAR-T after ASCT for high-risk newly diagnosed multiple myeloma","volume":"144","author":"Shi","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101638_bib106","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib107","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood-2024-202676","article-title":"Early safety and efficacy of CAR-T cell therapy in precursor myeloma: results of the CAR-PRISM study using ciltacabtagene autoleucel in high-risk smoldering myeloma","volume":"144","author":"Nadeem","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101638_bib108","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1182\/blood-2024-199913","article-title":"BCMA CAR-T therapy as first-line consolidation treatment in transplant-ineligible patients with newly-diagnosed multiple myeloma: an open label, single-arm, phase 2 study (CAREMM-001)","volume":"144","author":"Yan","year":"2024","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169262500043X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169262500043X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:39:21Z","timestamp":1762547961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169262500043X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S152169262500043X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101638","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adoptive cellular therapies in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101638"}}